Koichi Osaki
Overview
Explore the profile of Koichi Osaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamasaki S, Hashiguchi M, Yoshida-Sakai N, Jojima H, Osaki K, Okamura T, et al.
Hematol Rep
. 2024 Nov;
16(4):714-723.
PMID: 39584925
Background: The development of newer agents, including anti-CD38 monoclonal antibodies (mAbs), has significantly improved overall survival (OS) in patients with relapsed or refractory multiple myeloma (RRMM). However, the treatment of...
2.
Yamaguchi M, Takaki Y, Yamasaki Y, Oya S, Nakamura T, Morishige S, et al.
Rinsho Ketsueki
. 2024 Mar;
65(2):90-94.
PMID: 38448004
A 62-year-old woman was diagnosed as a hemophilia A carrier (factor VIII activity 35%) on preoperative examination of an ovarian tumor. A total of 35,600 units of recombinant factor VIII...
3.
Osaki K, Sogabe Y, Seki R, Nakamura T, Morishige S, Oku E, et al.
Kurume Med J
. 2022 Sep;
67(2.3):83-89.
PMID: 36123027
We investigated the molecular basis of factor VII (FVII) deficiency in a Japanese patient and identified compound heterozygous mutations. Factor VII activity and antigen levels in the patient were less...
4.
Yamasaki Y, Morishige S, Komaki S, Furuta T, Koga H, Oya S, et al.
Int J Hematol
. 2021 Jun;
114(4):502-508.
PMID: 34159518
Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus (EBV)-driven B-cell lymphoproliferative disease affecting mainly extranodal sites such as the lung, central nervous system (CNS), skin, kidney, and liver. We report...
5.
Mouri F, Yamasaki Y, Ohya S, Nakamura T, Morishige S, Yamaguchi M, et al.
Rinsho Ketsueki
. 2021 Feb;
62(1):7-13.
PMID: 33551430
Dose-adjusted (DA)-EPOCH-R causes profound neutropenia requiring relatively long hospital stays with multiple doses of granulocyte colony-stimulating factor (G-CSF). A single-dose pegylated G-CSF (PEG-G-CSF) has been used for the treatment of...
6.
Oya S, Yamasaki Y, Nakamura T, Morishige S, Yamaguchi M, Aoyama K, et al.
Rinsho Ketsueki
. 2020 Dec;
61(11):1605-1610.
PMID: 33298654
Multicentric Castleman disease (MCD) comprises a heterogeneous group of lymphoproliferative disorders. Interleukin 6 (IL-6) plays an important role in the MCD pathophysiology. Here, we report the case of a 17-year-old...
7.
Oya S, Morishige S, Ozawa H, Sasaki K, Semba Y, Yamasaki Y, et al.
Int J Hematol
. 2020 Sep;
113(2):285-289.
PMID: 32951102
BCR-ABL1-like acute lymphoblastic leukemia (ALL) is a neoplasm of lymphoblasts committed to the B-cell lineage that lack the BCR-ABL1 translocation but show a pattern of gene expression very similar to...
8.
Nakamura T, Morishige S, Ozawa H, Kuboyama K, Yamasaki Y, Oya S, et al.
Haemophilia
. 2020 Jul;
26(5):826-833.
PMID: 32700411
Background: Factor V (FV) deficiency is a monogenic inherited coagulation disorder considered to be an ideal indication for gene therapy. To investigate the possibility of therapeutic application of genome editing,...
9.
Morishige S, Mizuno S, Ozawa H, Nakamura T, Mazahery A, Nomura K, et al.
Int J Hematol
. 2019 Oct;
111(2):225-233.
PMID: 31664646
The clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system is an efficient genome-editing tool that holds potential for gene therapy. Here, we report an application of this system for...
10.
Morishige S, Nishi M, Saruta H, Arakawa F, Yamasaki Y, Oya S, et al.
Int J Hematol
. 2019 Jun;
110(4):506-511.
PMID: 31152415
Allogeneic hematopoietic cell transplantation (allo-HSCT) is considered the curative treatment option in patients with aggressive adult T cell leukemia/lymphoma (ATLL), but the treatment of relapse after allo-HSCT remains a major...